EA201490201A1 - Выявление экспрессии гена prame при раковом заболевании - Google Patents

Выявление экспрессии гена prame при раковом заболевании

Info

Publication number
EA201490201A1
EA201490201A1 EA201490201A EA201490201A EA201490201A1 EA 201490201 A1 EA201490201 A1 EA 201490201A1 EA 201490201 A EA201490201 A EA 201490201A EA 201490201 A EA201490201 A EA 201490201A EA 201490201 A1 EA201490201 A1 EA 201490201A1
Authority
EA
Eurasian Patent Office
Prior art keywords
detection
gene expression
cancer diseases
prame
prame gene
Prior art date
Application number
EA201490201A
Other languages
English (en)
Inventor
Катрин Минге
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201490201A1 publication Critical patent/EA201490201A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Настоящее изобретение относится к праймерам и зондам, специфичным в отношении PRAME, для применения новых диагностических наборов и способов. Данное изобретение дополнительно относится к лечению конкретных популяций пациентов с раковым заболеванием, страдающих от опухолей, экспрессирующих PRAME.
EA201490201A 2011-08-30 2012-08-30 Выявление экспрессии гена prame при раковом заболевании EA201490201A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1114919.2A GB201114919D0 (en) 2011-08-30 2011-08-30 Method
PCT/EP2012/066920 WO2013030310A1 (en) 2011-08-30 2012-08-30 Detection of prame gene expression in cancer

Publications (1)

Publication Number Publication Date
EA201490201A1 true EA201490201A1 (ru) 2014-11-28

Family

ID=44838891

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490201A EA201490201A1 (ru) 2011-08-30 2012-08-30 Выявление экспрессии гена prame при раковом заболевании

Country Status (14)

Country Link
US (1) US20140205635A1 (ru)
EP (1) EP2751282A1 (ru)
JP (1) JP2014527411A (ru)
KR (1) KR20140054399A (ru)
CN (1) CN103748238A (ru)
AU (1) AU2012300866A1 (ru)
BR (1) BR112014002404A2 (ru)
CA (1) CA2844178A1 (ru)
EA (1) EA201490201A1 (ru)
GB (1) GB201114919D0 (ru)
IL (1) IL230545A0 (ru)
MX (1) MX2014002478A (ru)
WO (1) WO2013030310A1 (ru)
ZA (1) ZA201400892B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014235380B2 (en) 2013-03-15 2020-03-19 Myriad Mypath, Llc Genes and gene signatures for diagnosis and treatment of melanoma
CA2953016A1 (en) 2014-07-02 2016-01-07 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
JP7216995B2 (ja) * 2018-12-05 2023-02-02 学校法人関西医科大学 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー
CN113136432A (zh) * 2021-05-06 2021-07-20 杭州艾迪康医学检验中心有限公司 检测aml中prame基因相对表达量的试剂及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
RU2118164C1 (ru) 1992-06-25 1998-08-27 Смитклайн Бичам Байолоджикалс, С.А. Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP2258872B1 (en) * 2002-03-13 2013-08-14 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
ES2314378T3 (es) * 2003-02-20 2009-03-16 Genomic Health, Inc. Uso de arn intronico para medir la expresion genica.
WO2004112825A2 (en) * 2003-06-17 2004-12-29 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
BRPI0806463A2 (pt) * 2007-01-15 2011-09-06 Glaxosmithkline Biolog Sa proteìna de fusão, seqüência de ácido nucleico, vetor, célula hospedeira, vacina, uso de uma proteìna ou ácido nucleico ou vetores, processo para a produção de uma proteìna de fusão, e, método para tratar um paciente que sofre de cáncer
CA2689714A1 (en) * 2007-06-01 2008-12-04 Agendia B.V. Prognostic gene expression signature for non small cell lung cancer patients
CA2781248A1 (en) * 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof

Also Published As

Publication number Publication date
CN103748238A (zh) 2014-04-23
GB201114919D0 (en) 2011-10-12
AU2012300866A1 (en) 2014-02-27
MX2014002478A (es) 2014-07-24
WO2013030310A1 (en) 2013-03-07
BR112014002404A2 (pt) 2017-02-21
US20140205635A1 (en) 2014-07-24
CA2844178A1 (en) 2013-03-07
IL230545A0 (en) 2014-03-31
JP2014527411A (ja) 2014-10-16
EP2751282A1 (en) 2014-07-09
ZA201400892B (en) 2016-09-28
KR20140054399A (ko) 2014-05-08

Similar Documents

Publication Publication Date Title
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
TN2013000412A1 (en) Bcma-based stratification and therapy for multiple myeloma patients
EA201590783A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EA201391154A3 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
EA201590998A1 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
EA201391074A1 (ru) Профили экспрессии генов рака толстой кишки и способы применения
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201500334A1 (ru) Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
EA201590747A1 (ru) Способы лечения с использованием аденовируса
EA201490180A1 (ru) Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
EA201401353A1 (ru) Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк)
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
IN2014DN08312A (ru)
WO2013188823A3 (en) Cancer prognostic assays